Facilities for Personalised Medicine in the Most Personal Form – Today and Tomorrow
Posted on September 7,2017
When redoing the batch is not an option There is a paradigm shift underway in which big pharma mass production of products for specific diseases is deviating towards the ‘batch of one.’ These autologous therapies are patient-specific and there may only be one chance to harvest the patient’s ce...
To read the full article and other articles in this issue, please register for an account or log in.
Related Topics and Keywords
ATMP, autologous therapies, batch of one, flexible Advanced Therapy Medicinal Product, GMP, Good Manufacturing Practice, Henriette Schubert, NNE A/S, patient-specific, Personalised Medicine, specific diseases, tailored and orphan drugs, targeted therapies, treatment of rare diseases